Table 3:
Multivariable analysis for relationship between inflammatory markers between sTWEAK, sCD163, sTWEAK/sCD163 and inflammatory and cardiovascular markers for HIV-infected patients with VL<50 copies/mL
| sTWEAK | sCD163 | sCD163/sTWEAK | ||||
|---|---|---|---|---|---|---|
| β (SE) | P value | β (SE) | P value | β (SE) | P value | |
| Demographics | ||||||
| Age, years | −125.42 (55.9) | 0.03 | 120.02 (26.80) | <0.01 | 0.20 (0.34) | <0.01 |
| Male sex | 53.19 (217.8) | 0.80 | 16.44 (67.90) | 0.81 | −0.02 (0.23) | 0.91 |
| Metabolic and cardiovascular risk factors | ||||||
| Waist Hip Ratio | −439.67 (972.10) | 0.65 | 988.36 (383.75) | 0.01 | 1.46 (0.74) | 0.05 |
| BMI, kg/m2 | −8.81 (10.59) | 0.41 | 9.31 (6.10) | 0.13 | 0.011 (0.01) | 0.18 |
| Hypertensive Medication | 602.42 (266.75) | 0.03 | −233.96 (137.86) | 0.10 | −0.56 (0.38) | 0.14 |
| HOMA-IR | −6.00 (14.20) | 0.67 | 1.144 (9.09) | 0.90 | 0.15 (0.01) | 0.21 |
| Cholesterol, mg/dL | 26.46 (97.51) | 0.79 | −61.43 (38.32) | 0.11 | −0.04 (0.05) | 0.41 |
| LDL, mg/dL | 96.84 (90.19) | 0.28 | −59.68 (35.58) | 0.09 | −0.06 (0.05) | 0.28 |
| HIV parameters | ||||||
| Nadir CD4+ count, cells/mm3 | 193.16 (116.58) | 0.10 | 0.033 (38.89) | 0.99 | −0.07 (0.06) | 0.20 |
| HIV RNA, copies/mL | −83544.14 (99169.93) | 0.40 | 62948.01 (44852.87) | 0.16 | 127.89 (63.99) | 0.05 |
| Measures of subclinical vascular disease | ||||||
| Mean-Mean common carotid artery IMT, mm | 1806.50 (685.16) | <0.01 | 678.82 (304.98) | 0.03 | −0.75 (0.37) | 0.05 |
| Mean-Max common carotid artery IMT, mm | 1128.18 (555.64) | 0.04 | 776.63 (199.34) | <0.01 | −0.13 (0.33) | 0.70 |
| Mean- mean carotid bulb IMT, mm | 65.76 (281.92) | 0.82 | 165.53 (106.64) | 0.12 | 0.15 (0.22) | 0.52 |
| Mean-Max Carotid Bulb IMT, mm | 371.17 (289.68) | 0.20 | 99.20 (94.18) | 0.29 | 0.04 (0.18) | 0.81 |
| Inflammation and Immune activation | ||||||
| hsCRP, μg/mL | 36.62 (55.62) | 0.51 | 13.31 (22.69) | 0.56 | 0.01 (0.04) | 0.82 |
| D-dimer, μg/mL | −10.61 (74.61) | 0.89 | −69.54 (34.62) | 0.05 | −0.00 (0.05) | 0.92 |
| Interleukin 6, pg/mL | 29.21 (7.06) | <0.01 | 6.59 (2.67) | 0.015 | −0.01 (0.00) | 0.11 |
| TNFα- receptor I, Pg/mL | −60.59 (54.96) | 0.27 | 91.07 (25.49) | <0.01 | 0.10 (0.05) | 0.06 |
| TNFα- receptor II, Pg/mL | 89.60 (96.40) | 0.35 | 87.78 (30.48) | <0.01 | −0.00 (0.06) | 0.90 |
| VCAM | −0.04 (100.10) | 1.00 | 72.46 (36.30) | 0.05 | 0.05 (0.07) | 0.45 |
| CD4+CD38+HLADR+T-cells, % | 17.86 (14.33) | 0.22 | 5.08 (6.00) | 0.40 | −0.00 (0.01) | 0.77 |
| CD8+CD38+HLADR+T-cells, % | 172.72 (118.55) | 0.15 | 5.48 (52.81) | 0.92 | −0.13 (0.13) | 0.31 |
| CD14+CD16+monocytes, % | −11.77 (5.15) | 0.02 | 7.93 (2.00) | <0.01 | 0.01 (0.01) | 0.06 |
| CD14dimCD16+monocytes, % | −30.14 (21.82) | 0.17 | 2.50 (8.35) | 0.77 | 0.04 (0.02) | 0.03 |
| sCD14, ng/mL | 11.73 (35.82) | 0.74 | 14.26 (16.23) | 0.38 | 0.2 (0.02) | 0.44 |
| sCD163, ng/mL | 0.54 (0.21) | 0.01 | ||||
All regression coefficients were adjusted for age, sex and race